功能性P2Y2核酸受体介导尿素5'-三酸盐诱导的内脏增生在子尾动脉
Cheikh I Seye1, Qiongman Kong, Laurie Erb
1Department of Biochemistry, University of Missouri-Columbia, Columbia, Mo 65212, USA. seyec@missouri.edu
Circulation
|November 20, 2002
概括
细胞外尿素5'-三酸 (UTP) 和腺5'-三酸 (ATP) 激活P2Y2受体,促进光滑肌肉细胞的增殖和内脏增生. 这项研究证明了P2Y2受体.
科学领域:
- 血管生物学 血管生物学
- 细胞信号传递 细胞信号传递
- 分子医学是分子医学.
背景情况:
- 细胞外尿素5'-三酸盐 (UTP) 通过P2Y2核酸受体激活平滑肌细胞 (SMC).
- P2Y2受体mRNA在内脏病变中升高,但其在内脏增生症中的作用尚不清楚.
研究的目的:
- 研究P2Y2受体在血管损伤和内脏增生中的作用.
- 为了确定P2Y2受体激活是否有助于SMC的扩散和新密的形成.
主要方法:
- 一个项圈模型被用来诱导子动脉中的血管损伤.
- Fura-2成像评估了SMC中的度变化,以应对P2Y受体激动剂.
- 测量了对UTP和ATP的反应,使用P2Y2反感性寡核酸抑制表达.
主要成果:
- 在新密度形成之前,SMC中的项圈放置调节了P2Y2受体mRNA.
- UTP和ATP,但不是UDP,增加了细胞内,证实了功能性P2Y2受体上调.
- 周血管UTP输液显著增强了新体的发育和巨细胞的透.
- UTP和ATP刺激了SMC中的骨质素表达,这种效应被P2Y2反感性寡核酸抑制.
结论:
- P2Y2受体在亲密增生症的发展中起着重要作用.
- 研究结果表明,P2Y2受体的激活有助于动脉样硬化和静脉复缩.
- 向P2Y2受体可能为血管增殖性疾病提供治疗策略.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
6.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81


